Bibliography
- ARMITAGE JO: Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood (1998) 92(12):4491–4508.
- MARKOWICZ S, ENGLEMAN EG: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. Clin. Invest. (1990) 85(3):955–961.
- SMALL EJ, REESE DM, UM B,WHISENANT S, DIXON SC, FIGG WD: Therapy of advanced prostate cancer with granulocyte macrophage colony- stimulating factor. Clin. Cancer Res. (1999) 5(7):1738–1744.
- •First report to establish the PSA modulating effect of systemic GM-CSE
- RINI BI, WEINBERG V, BOK R,SMALL EJ: Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. Clin. Oncol. (2003) 21(1):99–105.
- •Investigated the use of PSADT to measure biological effect of an immunotherapy agent.
- DREICER R, SEE WA, KLEIN EA: Phase II trial of GM-CSF in advanced prostate cancer. Invest. New Drugs (2001) 19(3)261–265.
- BUBLEY GJ, CARDUCCI M, DAHUT W et al.: Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. I Clin. Oncol (1999) 17(11):3461–3467.
- SMALL E, HIGANO C, SMITH D et al:A Phase II study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC).Frog. Proc. Am. Soc. Clin. Oncol (2004) (#4565).
- •Large Phase II trial with interesting immune results.
- MARASKOVSKY E, DARO E, ROUX E et al.: In vivo generation of human dendritic cell subsets by F1t3 ligand. Blood (2000) 96(3):878–884.
- LYNCH DH: Induction of dendritic cells (DC) by F1t3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit. Rev Immunol. (1998) 18(1-2):99–107.
- HIGANO CS, VOGELZANG NJ, SOSMAN JA, FENG A, CARON D, SMALL EJ: Safety and biological activity of repeated doses of recombinant human F1t3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clin. Cancer Res. (2004) 10(4):1219–1225.
- BURCH PA, BREEN JK, BUCKNER JC et al: Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. (2000) 6(6):2175–2182.
- SMALL EJ, FRATESI P, REESE DM et al: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. Clin. Oncol (2000) 18(23):3894–3903.
- •The first report of possible clinical activity with APC8015.
- BURCH PA, CROGHAN GA, GASTINEAU DA et al.: Immunotherapy (APC8015, Pmvenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase II trial. Prostate (2004) 60(3):197–204.
- SMALL EJ, PINT B, HIGANO C et al: A randomized, placebo-controlled Phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa) Proc. Am. Soc. Clin. Oncol (2003) 22:382 (abstract 1534).
- ••An initial Phase III report that prompted asecond Phase III trial.
- PRICE N: Improved survival benefit of autologous dendritic cell-based vaccine for hormone refractory prostate cancer: a retrospective subset analysis of the d9901 trial. Clin. Prostate Cancer (2004) 2(4):212.
- FONG L, BROCKSTEDT D, BENIKE C et al.: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. j. Immunol (2001) 167(12):7150–7156.
- FONG L, RUEGG CL,BROCKSTEDT D, ENGLEMAN EG, LAUS R: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. Immunol (1997) 159(7):3113–3117.
- HEISER A, COLEMAN D, DANNULL Jet al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. Clin. Invest. (2002) 109(3):409–417.